Ardelyx, Inc. (NASDAQ:ARDX) is among the best low priced stocks to get rich in 2026. On June 16, Ladenburg started coverage on Ardelyx, Inc. (NASDAQ:ARDX) with a Buy rating and a price target of $16. According to TheFly, the company is currently focused on expanding demand for Ibsrela, sustaining sales momentum for Xphozah, growing its pipeline, and meeting financial projections.
When Ardelyx, Inc. (NASDAQ:ARDX) reported its Q1 FY2026 results, its total product revenue was up 38% YoY, thanks to 58% YoY surge in IBSRELA revenue and strong XPHOZAH performance. While discussing IBSRELA, management laid out plans to deliver at least $1 billion in annual revenue in 2029. What strengthens the case for the company is its financial flexibility to make additional investments.
As stated by the President and CEO, Mike Raab,
"We're excited for this next phase of Ardelyx's evolution as we execute on our pipeline and explore various external opportunities that align with our mission and core capabilities and meet our disciplined capital allocation approach."
With a 1-year return outperformance of 42.18% and upside potential of 133.16%, Ardelyx, Inc. (NASDAQ:ARDX) is among the best low-priced stocks to get rich in 2026.